In a recent development, the European Medicines Agency's (EMA) human medicines committee (CHMP) has recommended against renewing the conditional marketing authorization for Blenrep (belantamab mafodotin), a medicine primarily used in the treatment of multiple myeloma, a form of cancer affecting the bone marrow. This decision comes after a thorough review of available data, including results from the DREAMM-3 study, which did not confirm the effectiveness of Blenrep as initially agreed upon when the conditional marketing authorization was granted.
Conditional Marketing Authorization: A Brief Overview
Conditional marketing authorization is granted to medicines that address unmet medical needs for serious diseases. This type of authorization allows a medicine to be approved based on less comprehensive data than normally required. It is considered when the benefits of providing the medicine outweigh any potential risks associated with its use while waiting for further evidence. Medicines under conditional marketing authorization are subject to specific post-authorization obligations, such as conducting additional studies, to generate comprehensive data.
Blenrep's Conditional Authorization and Obligations
Blenrep received its conditional marketing authorization in August 2020 due to its potential to address a critical unmet need for patients who had received at least four prior treatments, and for whom the disease did not respond to certain other types of cancer treatment. At the time of authorization, comparative data for Blenrep were not available. The CHMP therefore required the company marketing Blenrep to conduct a study comparing its safety and effectiveness with pomalidomide plus low-dose dexamethasone, another authorized treatment for relapsed/refractory multiple myeloma.
Study Results and Implications
The study, known as DREAMM-3, aimed to assess the effectiveness of Blenrep in comparison to the established treatment regimen. Unfortunately, the results did not show a significant difference in progression-free survival between the two groups. This measure of effectiveness was pivotal in confirming the medicine's authorized use. Consequently, the CHMP concluded that the effectiveness of Blenrep could not be confirmed, leading to the recommendation for non-renewal of its marketing authorization in the European Union.
Implications for Patients and Healthcare Professionals
For patients currently using Blenrep, it is crucial to consult with their healthcare providers to discuss suitable alternative treatment options. Healthcare professionals are advised not to initiate any new patients on Blenrep, and to inform existing patients about the discontinuation of the medicine.
The decision to not renew the conditional marketing authorization for Blenrep reflects the EMA's commitment to ensuring the safety and efficacy of medicines used in the treatment of serious diseases. While this may be a setback for some patients, it underscores the importance of rigorous evaluation and ongoing research in the field of medical treatment.
The EMA will now forward the CHMP’s opinion to the European Commission, which will issue a final legally binding decision applicable in all EU Member States. This decision serves as a reminder of the continuous efforts to provide the best possible care and treatment options for patients facing challenging medical conditions.
You can read more about it here: